We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
- Authors
Sekeres, Mikkael A; Maciejewski, Jaroslaw P; Giagounidis, Aristotle A N; Wride, Kenton; Knight, Robert; Raza, Azra; List, Alan F
- Abstract
Patients with myelodysplastic syndromes (MDS) often require treatment with growth factors (GFs) or non-GF therapies. One non-GF drug, lenalidomide, is particularly effective at achieving transfusion independence (TI) in patients with lower-risk MDS with the del(5q) cytogenetic abnormality. However, approximately half of del(5q) patients and one quarter of non-del(5q) patients treated with lenalidomide experience significant cytopenias. Lenalidomide-induced cytopenias occurring early in treatment may serve as a surrogate marker of clonal suppression and, therefore, may be predictive of a TI response.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 36, p5943
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.15.5770